Depot Preparations
Depot Preparations - Related Videos
08:30
Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots
0 Views •
Cited by 6 •
2015
Here, we present a protocol for encapsulation of catabolic cells, which consume lipids for heat production in intra-abdominal adipose tissue and increase energy dissipation in obese mice.
09:21
Human Brown Adipose Tissue Depots Automatically Segmented by Positron Emission Tomography/Computed Tomography and Registered Magnetic Resonance Images
0 Views •
Cited by 22 •
2015
The method presented here uses 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET-CT) and fat-water separated magnetic resonance imaging (MRI), each scanned following 2 hr exposure to thermoneutral (24 °C) and cold conditions (17 °C) in order to map brown adipose tissue (BAT) in adult human subjects.
03:41
Harvesting Peritoneal Fat Depots: A Technique to Study Ovarian Cancer Colonization of Peritoneal Adipose Tissues in Mouse Models
0 Views •
2023
In this video, we use a euthanized female mouse model bearing ovarian cancer. We then describe a protocol to identify and extract fat depots or adipose tissues associated with the five primary peritoneal organs to study metastatic cancer cell colonization.
08:52
Immunomagnetic Separation of Fat Depot-specific Sca1high Adipose-derived Stem Cells (ASCs)
0 Views •
Cited by 2 •
2016
We present the techniques required to isolate the stromal vascular fraction (SVF) from mouse inguinal (subcutaneous) and perigonadal (visceral) adipose tissue depots to assess their gene expression and collagenolytic activity. This method includes the enrichment of Sca1high adipose-derived stem cells (ASCs) using immunomagnetic cell separation.
08:53
Localization, Identification, and Excision of Murine Adipose Depots
0 Views •
Cited by 54 •
2014
Due to the drastic and negative connection between obesity and other comorbidities, research on the role adipose plays in disease and overall health is warranted. We present a protocol for the isolation and excision of adipose depots allowing for the study of adipose using in situ and in vitro methods.
FAQs
The release rate depends on how the formulation is built and on whether the active medicine leaves the depot by diffusion or dissolution. After release, the drug must be absorbed into the circulation. These linked steps determine how gradually therapeutic exposure is maintained, making release behavior central to clinical performance.
At the administration site, the depot acts as a temporary drug reservoir rather than delivering the full amount at once. Medicine leaves this reservoir progressively, then enters the circulation through absorption. This arrangement supports prolonged exposure from one administration and helps explain why depot preparations can reduce how often dosing is required.
Compared with repeatedly administered immediate-release formulations, depot preparations are intended to spread medicine release over a longer interval. The resulting exposure can be more consistent, while administration occurs less frequently. Clinically, that difference may support continuity of treatment and adherence, especially when regular repeated dosing is difficult.
Clinicians may consider a depot approach when maintaining treatment over time is important and fewer administrations could support adherence. The overview identifies particular relevance in hormone therapy, psychiatric care, contraception, and chronic conditions. In these settings, sustained delivery can help preserve continuity of care rather than relying on frequent immediate-release dosing.
The clinical value of sustained delivery can be assessed through its ability to maintain therapeutic exposure, provide more consistent drug levels, and reduce dosing frequency. These features can support continuity of care and may improve therapeutic outcomes, particularly when treatment requires ongoing medicine exposure rather than intermittent administration.
Their use spans hormone therapy, psychiatric care, contraception, and treatment of chronic conditions. Although these clinical settings differ, the shared rationale is sustained medicine delivery: patients can receive ongoing exposure with fewer administrations. This approach may make long-term treatment more continuous and support adherence when repeated dosing presents a challenge.